Abstract
Graves’ disease (GD) has a high recurrence rate despite various and adequate treatment. Numerous studies have been performed to identify the predictor of disease recurrence. This report aims to investigate the role of thyroid stimulating hormone (TSH) level as a thyrotropin in predicting the recurrence of Graves’ disease within 1 to 2 years following antithyroid drug (ATD) withdrawal. Literature searching was conducted on PubMed, Scopus, Cochrane, Proquest, EBSCO in August 2019 and Google Scholar in October 2020. The study criteria include the study that evaluates TSH level 4 weeks following ATD withdrawal, with subjects ≥18 years old who are retrospectively or prospectively followed up after 1 to 2 years following ATD withdrawal. Four eligible studies were selected based on inclusion/exclusion criteria, all of which measured TSH level at 4 weeks following ATD withdrawal. All studies had 1 to 2 years follow up. One study was an RCT, two studies were done in prospective cohort and another in retrospective cohort. All studies had comparable validity and applicability. Three out of four studies suggested that low TSH level measured 4 weeks following treatment withdrawal was associated with higher risk of disease recurrence. In conclusion, low TSH level obtained 4 weeks after ATD withdrawal was associated with higher rate of recurrence rate in GD.
Highlights
Graves’ disease (GD) is the most common autoimmune disorder with an incidence of 0.5% in the population [1,2,3,4,5]
GD is one of the most common causes of hyperthyroidism which accounts for 50–80% of this disorder besides toxic nodular goiter (TNG) [3,4,5,6,7,8]
Three out of four studies suggested that low thyroid stimulating hormone (TSH) level measured 4 weeks following treatment withdrawal was associated with higher risk of disease recurrence
Summary
Graves’ disease (GD) is the most common autoimmune disorder with an incidence of 0.5% in the population [1,2,3,4,5]. GD is one of the most common causes of hyperthyroidism which accounts for 50–80% of this disorder besides toxic nodular goiter (TNG) [3,4,5,6,7,8]. According to Indonesian National Health Survey in 2013, the prevalence of hyperthyroidism based on history taking was 0.4% and was found to be higher in women, urban population, and above 45 years old [9]. Serum TSH level as predictor of Graves’ disease recurrence following antithyroid withdrawal: Systematic review its population, consisting 0.5% overt hyperthyroidism and 0.7% subclinical hyperthyroidism [10]. The rate of recurrence of GD remains high, ranging from 37–50% in many studies [12,13,14]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
